Table 1.

Range of Evidence in Included Studies (80 manuscripts)

Experimental Criterion	(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)
Treatment before ischemia	Number of Studies by Criterion
Inhaled agents
Sevoflurane	12	12	yes	1/11	0	0	12	3	10	2
Isoflurane	15	16	yes	2/13	0	0	15	2	14	1
Desflurane	1	1	no	0	0	0	1	1	1	0
Intravenous agents
Propofol	2	2	yes	1/2	0	0	1	0	3	0
Remifentanil	1	1	no	0/1	0	0	1	0	1	0
Dexmedetomidine	1	0	no	0/1	0	0	1	0	1	0
Treatment during/after ischemia
Inhaled agents
Sevoflurane	6	8	yes	1/5	3	3	8	2	7	1
Isoflurane	16	26	yes	2/23	2	3	26	2	19	7
Desflurane	2	2	yes	0/2	0	0	2	2	2	0
Xenon	2	2	yes	0/2	0	0	2	2	2	0
Intravenous agents
Propofol	11	12	yes	3/9	0	0	8	2	12	0
Ketamine	1	2	yes	0/2	0	1	1	0	1	0
Barbiturates	2	2	yes	0/2	0	0	2	2	2	0

Assessment of functional (1) or histological (2) outcome; replicated in two or more laboratories (3), tested with permanent and temporary occlusion, (4) tested in females and males (5), tested in animals with comorbidities (diabetes, hypertension) (6) , clinically appropriate route of administration(7), dose-response relationship investigated (8), assessment in acute phase(9), assessment in chronic phase (10). Range of Evidence from Sena et al.⁸